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OBJECTIVE — We aimed to determine the effects of thyroid hormone on A1C and glycated
albumin (GA) in nondiabetic patients with overt hypothyroidism.
RESEARCHDESIGNANDMETHODS — A1Clevelsweremeasuredin45nondiabetic
patients with overt hypothyroidism and 180 euthyroid control subjects. A1C, GA, fasting blood
glucose(FBG),1,5-anhydroglucitol,anderythrocyteindexesweredeterminedin30nondiabetic
patients with overt hypothyroidism before and after thyroid hormone replacement.
RESULTS — A1C levels were higher in patients with hypothyroidism compared with control
subjects. A1C levels were decreased by thyroid hormone replacement. Thyroid hormone re-
placement increased serum erythropoietin, reticulocyte count, and mean corpuscular hemoglo-
bin (MCH). The change in A1C level was signiﬁcantly correlated with the change in reticulocyte
count or MCH. Thyroid hormone replacement decreased serum levels of albumin and GA.
However, FBG and 1,5-anhydroglucitol levels were not altered.
CONCLUSIONS — Levels of A1C and GA are spuriously high in nondiabetic patients with
overt hypothyroidism.
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A
1C is widely used for assessment of
glycemiccontrol,andtheAmerican
Diabetes Association (ADA) re-
cently recommended its use for diagnos-
ing diabetes and pre-diabetes (1). Serum
glycated albumin (GA) has been intro-
duced as a marker of short-term glycemia
(2). However, A1C or GA is subject to
certain limitations. Conditions that affect
erythrocyte turnover or survival lead to
falsely high or low A1C levels (3–6). GA
levelsmightbeinﬂuencedbyserumalbu-
min metabolism (2).
Thyroid hormone stimulates erythro-
cyte production, and hypothyroidism
often results in hypoproliferative erythro-
poiesis (7–8). In addition, thyroid hor-
mone promotes albumin metabolism,
and albumin degradation is reduced in
hypothyroidism (9). We therefore hy-
pothesized that A1C or GA levels do not
accurately reﬂect glycemia in hypothy-
roidism.Thus,weaimedtodeterminethe
effects of thyroid hormone on A1C and
GA levels in nondiabetic patients with
overt hypothyroidism.
RESEARCH DESIGN AND
METHODS— First, we performed a
cross-sectional study (study 1) in 45 non-
diabetic patients with thyroid cancer who
underwent thyroid hormone withdrawal
(THW) in preparation for radioiodine
treatment after a total thyroidectomy. Pa-
tients with diabetes, anemia, renal insuf-
ﬁciency, liver dysfunction, and severe
hypertriglyceridemia were excluded. For
control subjects, 180 age- and sex-
matched healthy euthyroid subjects were
enrolled. Fasting blood samples were ob-
tained for analysis of glucose, A1C, and
thyroid-stimulating hormone (TSH).
Second, a prospective trial (study 2)
was undertaken on nondiabetic patients
with thyroid cancer who underwent
THW during radioiodine treatment. Pa-
tients were evaluated at the end of the
4-week THW period (visit 1) and 8–12
weeks after subsequent thyroid hormone
replacement (visit 2). During visit 1,
fasting blood samples were obtained
from all patients for analysis of the
hemoglobin level, mean corpuscular
volume (MCV), mean corpuscular he-
moglobin (MCH), reticulocyte count,
and serum levels of erythropoietin
(EPO), TSH, free thyroxine (fT4), glu-
cose, A1C, GA, and 1,5-anhydrogluci-
tol (1,5-AG). These variables were
measured again during visit 2.
TheA1Clevelwasmeasuredusingan
automated high-performance liquid
chromatography analyzer (HLC-723 G7;
Tosoh Corporation, Tokyo, Japan). Intra-
and interassay coefﬁcients of variation
were 0.89 and 1.56%, respectively, at an
A1C of 5.6%. The GA level was measured
using an enzymatic method involving
albumin-speciﬁc proteinase, ketoamine
oxidase,andalbuminassayreagent(Lu-
cica GA-L; Asahi Kasei Pharma, Tokyo,
Japan). 1,5-AG level was measured us-
ing an enzymatic colorimetric assay
(GlycoMark; Tomen America, New
York, NY).
The paired Student t test or the Wil-
coxon signed rank test was used to com-
pare variables before and after thyroid
hormone replacement. Pearson correla-
tion analysis was conducted to assess as-
sociations between variables. P  0.05
was considered statistically signiﬁcant.
RESULTS— In study 1, TSH levels
were signiﬁcantly higher in patients with
overt hypothyroidism compared with the
control subjects. A1C levels were higher
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pared with the control subjects (5.54 
0.43 vs. 5.34  0.31%, P  0.001). In
contrast, fasting blood glucose (FBG) lev-
els were lower in patients with hypothy-
roidism than in the control subjects
(supplementary Table 1 in the online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc10-0988/DC1).
In study 2, 30 patients were consecu-
tively enrolled. After 4 weeks of THW, se-
rum TSH and fT4 levels were 84.5  20.7
mIU/l (reference range 0.38–4.94 mIU/l)
and 5.2 0.1 pmol/l (reference range 9.0–
24.9pmol/l),respectively.Afterradioiodine
treatment,patientsreceivedastandardpro-
tocol of thyroid hormone therapy. During
this period, serum TSH and fT4 levels were
0.2  0.5 mIU/l and 22.8  5.1 pmol/l,
respectively.
A1Cleveldecreasedafterthyroidhor-
mone replacement (from 5.57  0.26 to
5.370.32%,P0.001;Table1).Thy-
roid hormone replacement increased
EPO level, reticulocyte count, MCV, and
MCH. Thyroid hormone replacement de-
creased serum albumin level and GA
level.However,thyroidhormonereplace-
ment did not alter GA-to-A1C ratio, FBG,
or 1,5-AG level.
The change in A1C was correlated
with the change in reticulocyte count
( 0.381, P  0.042) and the change
in MCH ( 0.466, P  0.010).
Six patients were evaluated before to-
tal thyroidectomy (euthyroidism), after
THW (hypothyroidism), and after thy-
roid hormone replacement (euthyroid-
ism). A1C levels tended to increase
during hypothyroidism (from 5.52 
0.25 to 5.63  0.28%, P  0.082) and
then return to baseline levels (from
5.520.25to5.500.29%,P0.426)
(supplementary Fig. 1).
CONCLUSIONS— We found that
A1Clevelsweresigniﬁcantlyhigherinpa-
tients with overt hypothyroidism com-
pared with control subjects. In addition,
A1C levels decreased after thyroid hor-
mone replacement in patients with overt
hypothyroidism. Serum EPO level, re-
ticulocyte count, and MCH increased af-
ter thyroid hormone replacement,
suggesting that thyroid hormone stimu-
lates erythropoiesis. Moreover, the
change in A1C level was negatively corre-
lated with the change in reticulocyte
count and MCH. These data suggest that
thyroid hormone replacement is associ-
atedwithadecreaseinA1Clevel,whichis
inﬂuenced by increased erythropoiesis
rather than by changes in glucose level.
Ten of 30 patients (33%) had an A1C
5.7%duringoverthypothyroidism,but
afterthyroidhormonereplacementonly4
of 30 patients (13%) had an A1C 5.7%.
The ADA Expert Committee recently en-
dorsed an A1C of 5.7–6.4% as indicative
of pre-diabetes (1). According to these
criteria, 20% of our subjects (6 of 30 pa-
tients) were misclassiﬁed as having pre-
diabetes. However, use of A1C for
diagnosing pre-diabetes is not universally
accepted.
GA levels decrease in patients with
nephrotic syndrome, which shortens the
half-lifeofserumalbumin,andincreasein
patients with liver cirrhosis, which pro-
longs the half-life of serum albumin (2).
Albumin metabolism is prolonged in
hypothyroidism, and thyroid hormone
promotes albumin metabolism. We dem-
onstrated that GA levels decreased, along
with serum albumin levels, after thyroid
hormone replacement.
Although abnormal glucose metab-
olism is common in thyrotoxicosis, the ef-
fect of overt hypothyroidism on glucose
metabolism is still a subject of debate (10–
11). In our study, GA-to-A1C ratio, FBG,
and1,5-AGlevel(amarkerforpostprandial
hyperglycemia) (12) were not altered by
thyroid hormone replacement.
The limitation of this study includes
the fact that patient selection was nar-
rowed by choosing iatrogenic hypothy-
roid patients prior to radioiodine
treatment. Second, we did not measure
erythrocyte life span.
In conclusion, our data suggest that
nondiabetic patients with overt hypo-
thyroidism showed spuriously high
levels of A1C and GA. Therefore, the
effects of thyroid hormone on A1C and
GA must be considered when interpret-
ing these parameters in patients with
thyroid disorders.
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